akusherstvoObstetrics, Gynecology and ReproductionАкушерство, Гинекология и Репродукция2313-73472500-3194IRBIS LLC10.17749/2313-7347/ob.gyn.rep.2026.699akusherstvo-2639Research ArticleREVIEW ARTICLEНАУЧНЫЙ ОБЗОРThe role of luteinizing hormone activity in controlled ovarian stimulation for assisted reproductive technologiesРоль активности лютеинизирующего гормона в контролируемой стимуляции яичников при вспомогательных репродуктивных технологияхhttps://orcid.org/0009-0002-6161-4084ЧупринаО. А.ChuprinaO. A.

Чуприна Оксана Александровна

350063 Краснодар, ул. Митрофана Седина, д. 4

Oksana A. Chuprina

4 Mitrofana Sedina Str., Krasnodar 350063

oksachuprina@yandex.ruhttps://orcid.org/0009-0001-3586-9991РахматуллинФ. Р.RakhmatullinF. R.

Рахматуллин Фанис Ражапович

450008 Уфа, ул. Ленина, д. 3

Fanis R. Rakhmatullin

3 Lenin Str., Ufa 450008

https://orcid.org/0009-0009-0723-7733ПеченикЛ. И.PechenikL. I.

Печеник Лира Игоревна

344022 Ростов-на-Дону, Нахичеванский переулок, д. 29

Lira I. Pechenik

29 Nahichevansky Lane, Rostov-on-Don 344022

https://orcid.org/0009-0001-7864-9219НемеровскаяТ. Ф.NemerovskaiaT. F.

Немеровская Татьяна Федоровна

344022 Ростов-на-Дону, Нахичеванский переулок, д. 29

Tatiana F. Nemerovskaia

29 Nahichevansky Lane, Rostov-on-Don 344022

https://orcid.org/0009-0006-4750-3221АйдиноваР. М.AidinovaR. M.

Айдинова Радима Мурадиновна 

344022 Ростов-на-Дону, Нахичеванский переулок, д. 29

Radima M. Aidinova

29 Nahichevansky Lane, Rostov-on-Don 344022

https://orcid.org/0009-0005-1723-0130МеркуловаВ. Н.MerkulovaV. N.

Меркулова Виктория Николаевна

344022 Ростов-на-Дону, Нахичеванский переулок, д. 29

Victoria N. Merkulova

29 Nahichevansky Lane, Rostov-on-Don 344022

https://orcid.org/0009-0001-8850-5059ГузийВ. В.GuziiV. V.

Гузий Варвара Владимировна

344022 Ростов-на-Дону, Нахичеванский переулок, д. 29

Varvara V. Guzii

29 Nahichevansky Lane, Rostov-on-Don 344022

https://orcid.org/0009-0002-9411-9071ШульгаЕ. П.ShulgaE. P.

344022 Ростов-на-Дону, Нахичеванский переулок, д. 29

Elizaveta P. Shulga

29 Nahichevansky Lane, Rostov-on-Don 344022

https://orcid.org/0009-0001-9588-0754ГалинаА. Р.GalinaA. R.

Галина Аделина Руслановна

450008 Уфа, ул. Ленина, д. 3

Adelina R. Galina

3 Lenin Str., Ufa 450008

https://orcid.org/0009-0009-5910-3411ГарееваЭ. Ф.GareevaE. F.

Гареева Эльвина Фазитовна

450008 Уфа, ул. Ленина, д. 3

Elvina F. Gareeva

3 Lenin Str., Ufa 450008

https://orcid.org/0009-0000-3361-4074РоговаЕ. И.RogovaE. I.

Рогова Екатерина Ильинична

295007 Симферополь, проспект академика Вернадского, д. 4

Ekaterina I. Rogova

4 Academician Vernadsky Avenue, Simferopol 295007

https://orcid.org/0009-0004-4797-1434КебедоваА. М.KebedovaA. M.

Кебедова Аида Мусагаджиевна

117513 Москва, ул. Островитянова, д. 1

Aida M. Kebedova

1 Ostrovityanova Str., Moscow 117513

https://orcid.org/0009-0009-2538-6265ОгурлиевД. А.OgurlievD. A.

Огурлиев Далгат Алимович

367005 Махачкала, площадь Ленина, д. 1

Dalgat A. Ogurliev

1 Lenin Square, Makhachkala, 367005 

https://orcid.org/0009-0008-7331-9991ДресвянкинГ. С.DresvyankinG. S.

Дресвянкин Григорий Станиславович

620028 Екатеринбург, ул. Репина, д. 3

Grigory S. Dresvyankin

3 Repina Str., Еkaterinburg 620028

ФГБОУ ВО «Кубанский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияKuban State Medical University, Ministry of Health of the Russian FederationRussian FederationФГБОУ ВО «Башкирский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияBashkir State Medical University, Ministry of Health of the Russian FederationRussian FederationФГБОУ ВО «Ростовский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияRostov State Medical University, Ministry of Health of the Russian FederationRussian FederationФГАОУ ВО «Крымский федеральный университет имени В.И. Вернадского»РоссияVernadsky Crimean Federal UniversityRussian FederationФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Министерства здравоохранения Российской ФедерацииРоссияPirogov Russian National Research Medical University, Ministry of Health of the Russian FederationRussian FederationФГБОУ ВО «Дагестанский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияDagestan State Medical University, Ministry of Health of the Russian FederationRussian FederationФГБОУ ВО «Уральский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияUral State Medical University, Ministry of Health of the Russian FederationRussian Federation20261301202600Online First2639Copyright © Chuprina O.A., Rakhmatullin F.R., Pechenik L.I., Nemerovskaia T.F., Aidinova R.M., Merkulova V.N., Guzii V.V., Shulga E.P., Galina A.R., Gareeva E.F., Rogova E.I., Kebedova A.M., Ogurliev D.A., Dresvyankin G.S., 20262026Чуприна О.А., Рахматуллин Ф.Р., Печеник Л.И., Немеровская Т.Ф., Айдинова Р.М., Меркулова В.Н., Гузий В.В., Шульга Е.П., Галина А.Р., Гареева Э.Ф., Рогова Е.И., Кебедова А.М., Огурлиев Д.А., Дресвянкин Г.С.Chuprina O.A., Rakhmatullin F.R., Pechenik L.I., Nemerovskaia T.F., Aidinova R.M., Merkulova V.N., Guzii V.V., Shulga E.P., Galina A.R., Gareeva E.F., Rogova E.I., Kebedova A.M., Ogurliev D.A., Dresvyankin G.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gynecology.su/jour/article/view/2639

Luteinizing hormone (LH) activity plays a key role in regulating folliculogenesis, ovulation, and luteinization by determining the effectiveness of controlled ovarian stimulation (COS) protocols in assisted reproductive technologies (ART). LH stimulates androgen synthesis in theca cells serving as a platform for estrogen production in granulosa cells driven by follicle-stimulating hormone (FSH), and regulates receptor expression, oocyte meiotic maturation, and luteal phase formation. Current evidence indicates that a balanced combination of FSH and LH activity is essential for optimal follicular growth and full oocyte maturation. LH deficiency leads to decreased estradiol production, impaired steroidogenesis, and reduced fertilization outcomes. The addition of active LH-containing supplements improves treatment efficacy in women with hypogonadotropic hypogonadism, diminished ovarian reserve, ovarian hyporesponsiveness, as well as in older reproductive-age patients and those undergoing gonadotropin-releasing hormone antagonist protocols. The use of human menopausal gonadotropin and its highly purified form, as well as recombinant LH, enhances hormonal balance, improves oocyte and embryo quality, and reduces the risk of ovarian hyperstimulation syndrome. Incorporation of LH activity into COS regimens supports more physiological follicular maturation and a balanced steroid response. Optimization of LH dosing and timing, along with personalized therapy based on patient age, ovarian reserve, and genetic characteristics, increases ART efficacy, improves treatment outcomes, and ensures a safer and more predictable reproductive result.

Активность лютеинизирующего гормона (ЛГ) играет ключевую роль в регуляции фолликулогенеза, овуляции и лютеинизации, определяя эффективность протоколов контролируемой стимуляции яичников (КСЯ) при вспомогательных репродуктивных технологиях (ВРТ). ЛГ обеспечивает синтез андрогенов в тека-клетках, которые служат субстратом для образования эстрогенов в клетках гранулезы под действием фолликулостимулирующего гормона (ФСГ), а также регулирует экспрессию рецепторов, мейотическое созревание ооцита и формирование лютеиновой фазы. Современные исследования показывают, что сбалансированное сочетание активности ФСГ и ЛГ необходимо для оптимального роста фолликулов и полноценного созревания яйцеклеток. Дефицит ЛГ приводит к снижению уровня эстрадиола, нарушению стероидогенеза и ухудшению показателей оплодотворения. Добавление препаратов с активностью ЛГ повышает эффективность лечения у женщин с гипогонадотропным гипогонадизмом, сниженным овариальным резервом, гипореактивностью яичников, а также у пациенток старшего репродуктивного возраста и при применении антагонистов гонадотропин-рилизинг-гормона. Использование человеческого менопаузального гонадотропина и его высокоочищенной формы, а также рекомбинантного ЛГ способствует улучшению гормонального профиля, повышению качества ооцитов и эмбрионов, а также снижению риска синдрома гиперстимуляции яичников. Включение активности ЛГ в схемы КСЯ обеспечивает более физиологичное созревание фолликулов и сбалансированный стероидный ответ. Оптимизация дозировки и сроков введения ЛГ, а также персонализация терапии с учетом возраста, овариального резерва и генетических особенностей пациентки позволяют повысить эффективность ВРТ, улучшить исходы лечения и обеспечить более безопасный и предсказуемый репродуктивный результат.

лютеинизирующий гормонЛГактивность ЛГконтролируемая стимуляция яичниковКСЯвспомогательные репродуктивные технологииВРТчеловеческий менопаузальный гонадотропинрекомбинантный ЛГфолликулогенезовариальный резервгипореактивность яичниковстероидогенезluteinizing hormoneLHLH activitycontrolled ovarian stimulationassisted reproductive technologieshuman menopausal gonadotropinrecombinant LHfolliculogenesisovarian reserveovarian hyporesponsivenesssteroidogenesisReferencesАнварова Ш.А., Шукуров Ф.И., Туламетова Ш.А. Инновационные методы решения проблемы женского бесплодия, ассоциированного с эндокринными нарушениями. Акушерство, Гинекология и Репродукция. 2024;18(5):706–19. https://doi.org/10.17749/2313-7347/ob.gyn.rep.2024.514.Anvarova Sh.A., Shukurov F.I., Tulametova Sh.A. Innovative methods for solving the problem of female infertility associated with endocrine disorders. [Innovacionnye metody resheniya problemy zhenskogo besplodiya, associirovannogo s endokrinnymi narusheniyami]. Obstetrics, Gynecology and Reproduction. 2024;18(5):706–19. (In Russ.). https://doi.org/10.17749/2313-7347/ob.gyn.rep.2024.514.Курцер М.А., Касьянова Г.В., Овчинникова М.М., Хетагурова Д.Т. Ретроспективное сравнительное исследование исходов вспомогательных репродуктивных технологий у женщин в программах экстракорпорального оплодотворения с применением рекомбинантных гонадотропинов. Акушерство, Гинекология и Репродукция. 2022;16(3):277–86. https://doi.org/10.17749/2313-7347/ob.gyn.rep.2022.304.Kurtser M.A., Kasyanova G.V., Ovchinnikova M.M., Khetagurova D.T. Retrospective comparative study on artificial reproductive technology outcomes in women undergoing in vitro fertilization with recombinant gonadotropins. [Retrospektivnoe sravnitel'noe issledovanie iskhodov vspomogatel'nyh reproduktivnyh tekhnologij u zhenshchin v programmah ekstrakorporal'nogo oplodotvoreniya s primeneniem rekombinantnyh gonadotropinov]. Obstetrics, Gynecology and Reproduction. 2022;16(3):277–86. (In Russ.). https://doi.org/10.17749/2313-7347/ob.gyn.rep.2022.304.Башмакова Н.В., Новоселова Е.Н., Назаренко Т.А. и др. Реальная клиническая практика лечения бесплодия в России: мнение 425 врачей-репродуктологов. Акушерство, Гинекология и Репродукция. 2023;17(6):680–706. https://doi.org/10.17749/2313-7347/ob.gyn.rep.2023.468.Bashmakova N.V., Novoselova E.N., Nazarenko T.A. et al. Real clinical practice of infertility treatment in Russia: a collective opinion of 425 reproductologists. [Real'naya klinicheskaya praktika lecheniya besplodiya v Rossii: mnenie 425 vrachej-reproduktologov]. Obstetrics, Gynecology and Reproduction. 2023;17(6):680–706. (In Russ.) https://doi.org/10.17749/2313-7347/ob.gyn.rep.2023.468.Орлова Н.А., Ковнир С.В., Ходак Ю.А. и др. Рекомбинантный лютеинизирующий гормон человека для терапии бесплодия: получение линий-продуцентов. Акушерство, Гинекология и Репродукция. 2017;11(3):33–42. https://doi.org/10.17749/2313-7347.2017.11.3.033-042.Orlova N.A., Kovnir S.V., Khodak Yu.A. et al. Recombinant human luteinizing hormone for the treatment of infertility: the generation of producer cell lines. [Rekombinantnyj lyuteiniziruyushchij gormon cheloveka dlya terapii besplodiya: poluchenie linij-producentov]. Obstetrics, Gynecology and Reproduction. 2017;11(3):33–42. (In Russ.). https://doi.org/10.17749/2313-7347.2017.11.3.033-042.Боярский К.Ю. Влияние гликозилирования молекулы ФСГ на фолликулярную динамику и овариальную стимуляцию в программах ЭКО/ИКСИ (обзор литературы). Проблемы репродукции. 2012;(4):40–4.Boiarskiĭ K.Iu. Influence of glycosylation of FSH on follicular dynamics and ovarian stimulation in IVF/ICSI programs. [Vliyanie glikozilirovaniya molekuly FSG na follikulyarnuyu dinamiku i ovarial'nuyu stimulyaciyu v programmah EKO/IKSI (obzor literatury)]. Problemy reprodukcii. 2012;(4):40–4. (In Russ.)Cole L.A. Biological functions of hCG and hCG-related molecules. Reprod Biol Endocrinol. 2010;8:102. https://doi.org/10.1186/1477-7827-8-102.Cole L.A. Biological functions of hCG and hCG-related molecules. Reprod Biol Endocrinol. 2010;8:102. https://doi.org/10.1186/1477-7827-8-102.Arroyo A. Kim B., Yeh J. Luteinizing hormone action in human oocyte maturation and quality: signaling pathways, regulation, and clinical impact. Reprod Sci. 2020;27(6):1223–52. https://doi.org/10.1007/s43032-019-00137-x.Arroyo A. Kim B., Yeh J. Luteinizing hormone action in human oocyte maturation and quality: signaling pathways, regulation, and clinical impact. Reprod Sci. 2020;27(6):1223–52. https://doi.org/10.1007/s43032-019-00137-x.Mao R., Hou X., Feng X. et al. Recombinant human luteinizing hormone increases endometrial thickness in women undergoing assisted fertility treatments: a systematic review and meta-analysis. Front Pharmacol. 2024;15:1434625. https://doi.org/10.3389/fphar.2024.1434625.Mao R., Hou X., Feng X. et al. Recombinant human luteinizing hormone increases endometrial thickness in women undergoing assisted fertility treatments: a systematic review and meta-analysis. Front Pharmacol. 2024;15:1434625. https://doi.org/10.3389/fphar.2024.1434625.Di Segni N., Busnelli A., Secchi M. et al. Luteinizing hormone supplementation in women with hypogonadotropic hypogonadism seeking fertility care: Insights from a narrative review. Front Endocrinol (Lausanne). 2022;13:907249. https://doi.org/10.3389/fendo.2022.907249.Di Segni N., Busnelli A., Secchi M. et al. Luteinizing hormone supplementation in women with hypogonadotropic hypogonadism seeking fertility care: Insights from a narrative review. Front Endocrinol (Lausanne). 2022;13:907249. https://doi.org/10.3389/fendo.2022.907249.Anderson R.C., Newton C.L., Anderson R.A., Millar R.P. Gonadotropins and their analogs: current and potential clinical applications. Endocr Rev. 2018;39(6):911–37. https://doi.org/10.1210/er.2018-00052.Anderson R.C., Newton C.L., Anderson R.A., Millar R.P. Gonadotropins and their analogs: current and potential clinical applications. Endocr Rev. 2018;39(6):911–37. https://doi.org/10.1210/er.2018-00052.Casarini L., Simoni M. Recent advances in understanding gonadotropin signaling. Fac Rev. 2021;10:41. https://doi.org/10.12703/r/10-41.Casarini L., Simoni M. Recent advances in understanding gonadotropin signaling. Fac Rev. 2021;10:41. https://doi.org/10.12703/r/10-41.Smits G., Campillo M., Govaerts C. et al. Glycoprotein hormone receptors: determinants in leucine-rich repeats responsible for ligand specificity. EMBO J. 2003;22(11):2692–703. https://doi.org/10.1093/emboj/cdg260.Smits G., Campillo M., Govaerts C. et al. Glycoprotein hormone receptors: determinants in leucine-rich repeats responsible for ligand specificity. EMBO J. 2003;22(11):2692–703. https://doi.org/10.1093/emboj/cdg260.Duan J., Xu P., Cheng X. et al. Structures of full-length glycoprotein hormone receptor signalling complexes. Nature. 2021;598(7882):688–92. https://doi.org/10.1038/s41586-021-03924-2.Duan J., Xu P., Cheng X. et al. Structures of full-length glycoprotein hormone receptor signalling complexes. Nature. 2021;598(7882):688–92. https://doi.org/10.1038/s41586-021-03924-2.Duan J., Xu P., Zhang H. et al. Mechanism of hormone and allosteric agonist mediated activation of follicle stimulating hormone receptor. Nat Commun. 2023;14(1):519. https://doi.org/10.1038/s41467-023-36170-3.Duan J., Xu P., Zhang H. et al. Mechanism of hormone and allosteric agonist mediated activation of follicle stimulating hormone receptor. Nat Commun. 2023;14(1):519. https://doi.org/10.1038/s41467-023-36170-3.Troppmann B., Kleinau G., Krause G., Gromoll J. Structural and functional plasticity of the luteinizing hormone/choriogonadotrophin receptor. Hum Reprod Update. 2013;19(5):583–602. https://doi.org/10.1093/humupd/dmt023.Troppmann B., Kleinau G., Krause G., Gromoll J. Structural and functional plasticity of the luteinizing hormone/choriogonadotrophin receptor. Hum Reprod Update. 2013;19(5):583–602. https://doi.org/10.1093/humupd/dmt023.Grzesik P., Kreuchwig A., Rutz C. et al. Differences in signal activation by LH and hCG are mediated by the LH/CG receptor's extracellular hinge region. Front Endocrinol (Lausanne). 2015;6:140. https://doi.org/10.3389/fendo.2015.00140.Grzesik P., Kreuchwig A., Rutz C. et al. Differences in signal activation by LH and hCG are mediated by the LH/CG receptor's extracellular hinge region. Front Endocrinol (Lausanne). 2015;6:140. https://doi.org/10.3389/fendo.2015.00140.Riccetti L., Yvinec R., Klett D. et al. Human luteinizing hormone and chorionic gonadotropin display biased agonism at the LH and LH/CG receptors. Sci Rep. 2017;7(1):940. https://doi.org/10.1038/s41598-017-01078-8.Riccetti L., Yvinec R., Klett D. et al. Human luteinizing hormone and chorionic gonadotropin display biased agonism at the LH and LH/CG receptors. Sci Rep. 2017;7(1):940. https://doi.org/10.1038/s41598-017-01078-8.Casarini L., Santi D., Brigante G., Simoni M. Two hormones for one receptor: evolution, biochemistry, actions, and pathophysiology of LH and hCG. Endocr Rev. 2018;39(5):549–92. https://doi.org/10.1210/er.2018-00065.Casarini L., Santi D., Brigante G., Simoni M. Two hormones for one receptor: evolution, biochemistry, actions, and pathophysiology of LH and hCG. Endocr Rev. 2018;39(5):549–92. https://doi.org/10.1210/er.2018-00065.Jonas K.C., Chen S., Virta M. et al. Temporal reprogramming of calcium signalling via crosstalk of gonadotrophin receptors that associate as functionally asymmetric heteromers. Sci Rep. 2018;8(1):2239. https://doi.org/10.1038/s41598-018-20722-5.Jonas K.C., Chen S., Virta M. et al. Temporal reprogramming of calcium signalling via crosstalk of gonadotrophin receptors that associate as functionally asymmetric heteromers. Sci Rep. 2018;8(1):2239. https://doi.org/10.1038/s41598-018-20722-5.Simoni M., Paradiso E., Lockhart V. et al. Pleotropism of gonadotropin action. LE STUDIUM Multidisciplinary Journal. 2020:4:1–7. https://doi.org/10.34846/le-studium.194.02.fr.03-2020.Simoni M., Paradiso E., Lockhart V. et al. Pleotropism of gonadotropin action. LE STUDIUM Multidisciplinary Journal. 2020:4:1–7. https://doi.org/10.34846/le-studium.194.02.fr.03-2020.Conforti A., Di Girolamo R., Guida M. et al. Pharmacogenomic of LH and its receptor: are we ready for clinical practice? Reprod Biol Endocrinol. 2025;23(Suppl 1):29. https://doi.org/10.1186/s12958-025-01359-2.Conforti A., Di Girolamo R., Guida M. et al. Pharmacogenomic of LH and its receptor: are we ready for clinical practice? Reprod Biol Endocrinol. 2025;23(Suppl 1):29. https://doi.org/10.1186/s12958-025-01359-2.Casarini L., Riccetti L., De Pascali F. et al. Estrogen modulates specific life and death signals induced by LH and hCG in human primary granulosa cells in vitro. Int J Mol Sci. 2017;18(5):926. https://doi.org/10.3390/ijms18050926.Casarini L., Riccetti L., De Pascali F. et al. Estrogen modulates specific life and death signals induced by LH and hCG in human primary granulosa cells in vitro. Int J Mol Sci. 2017;18(5):926. https://doi.org/10.3390/ijms18050926.La Marca A., Longo M., Sighinolfi G. et al. New insights into the role of LH in early ovarian follicular growth: a possible tool to optimize follicular recruitment. Reprod Biomed Online. 2023;47(6):103369. https://doi.org/10.1016/j.rbmo.2023.103369.La Marca A., Longo M., Sighinolfi G. et al. New insights into the role of LH in early ovarian follicular growth: a possible tool to optimize follicular recruitment. Reprod Biomed Online. 2023;47(6):103369. https://doi.org/10.1016/j.rbmo.2023.103369.Shoham Z. The clinical therapeutic window for luteinizing hormone in controlled ovarian stimulation. Fertil Steril. 2002;77(6):1170–7. https://doi.org/10.1016/s0015-0282(02)03157-6.Shoham Z. The clinical therapeutic window for luteinizing hormone in controlled ovarian stimulation. Fertil Steril. 2002;77(6):1170–7. https://doi.org/10.1016/s0015-0282(02)03157-6.Lisi F., Rinaldi L., Fishel S. et al. Use of recombinant follicle-stimulating hormone (Gonal F) and recombinant luteinizing hormone (Luveris) for multiple follicular stimulation in patients with a suboptimal response to in vitro fertilization. Fertil Steril. 2003а;79(4):1037–8. https://doi.org/10.1016/s0015-0282(02)04917-8.Lisi F., Rinaldi L., Fishel S. et al. Use of recombinant follicle-stimulating hormone (Gonal F) and recombinant luteinizing hormone (Luveris) for multiple follicular stimulation in patients with a suboptimal response to in vitro fertilization. Fertil Steril. 2003а;79(4):1037–8. https://doi.org/10.1016/s0015-0282(02)04917-8.Bosch E., Alviggi C., Lispi M. et al. Reduced FSH and LH action: implications for medically assisted reproduction. Hum Reprod. 2021;36(6):1469–80. https://doi.org/10.1093/humrep/deab065.Bosch E., Alviggi C., Lispi M. et al. Reduced FSH and LH action: implications for medically assisted reproduction. Hum Reprod. 2021;36(6):1469–80. https://doi.org/10.1093/humrep/deab065.Бабичев В.Н. Организация и функционирование нейроэндокринной системы. Проблемы эндокринологии. 2013;59(1):62–9.Babichev V.N. Organization and functioning of the neuroendocrine system. [Organizaciya i funkcionirovanie nejroendokrinnoj sistemy]. Problemy endokrinologii. 2013;59(1):62–9. (In Russ.).Wu .J, Nayudu P.L., Kiesel P.S., Michelmann H.W. Luteinizing hormone has a stage-limited effect on preantral follicle development in vitro. Biol Reprod. 2000;63(1):320–7. https://doi.org/10.1095/biolreprod63.1.320.Wu .J, Nayudu P.L., Kiesel P.S., Michelmann H.W. Luteinizing hormone has a stage-limited effect on preantral follicle development in vitro. Biol Reprod. 2000;63(1):320–7. https://doi.org/10.1095/biolreprod63.1.320.Hill M.J., Levens E.D., Levy G. et al. The use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age: a systematic review and meta-analysis. Fertil Steril. 2012;97(5):1108–14.e1. https://doi.org/10.1016/j.fertnstert.2012.01.130.Hill M.J., Levens E.D., Levy G. et al. The use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age: a systematic review and meta-analysis. Fertil Steril. 2012;97(5):1108–14.e1. https://doi.org/10.1016/j.fertnstert.2012.01.130.Conforti A., Esteves S.C., Di Rella F. et al. The role of recombinant LH in women with hypo-response to controlled ovarian stimulation: a systematic review and meta-analysis. Reprod Biol Endocrinol. 2019;17(1):18. https://doi.org/10.1186/s12958-019-0460-4.Conforti A., Esteves S.C., Di Rella F. et al. The role of recombinant LH in women with hypo-response to controlled ovarian stimulation: a systematic review and meta-analysis. Reprod Biol Endocrinol. 2019;17(1):18. https://doi.org/10.1186/s12958-019-0460-4.Santi D., Casarini L., Alviggi C., Simoni M. Efficacy of follicle-stimulating hormone (FSH) alone, FSH + luteinizing hormone, human menopausal gonadotropin or FSH + human chorionic gonadotropin on assisted reproductive technology outcomes in the "personalized" medicine era: a meta-analysis. Front Endocrinol (Lausanne). 2017;8:114. https://doi.org/10.3389/fendo.2017.00114.Santi D., Casarini L., Alviggi C., Simoni M. Efficacy of follicle-stimulating hormone (FSH) alone, FSH + luteinizing hormone, human menopausal gonadotropin or FSH + human chorionic gonadotropin on assisted reproductive technology outcomes in the "personalized" medicine era: a meta-analysis. Front Endocrinol (Lausanne). 2017;8:114. https://doi.org/10.3389/fendo.2017.00114.Nair A.K., Peegel H., Menon K.M. The role of luteinizing hormone/human chorionic gonadotropin receptor-specific mRNA binding protein in regulating receptor expression in human ovarian granulosa cells. J Clin Endocrinol Metab. 2006;91(6):2239–43. https://doi.org/10.1210/jc.2005-2739.Nair A.K., Peegel H., Menon K.M. The role of luteinizing hormone/human chorionic gonadotropin receptor-specific mRNA binding protein in regulating receptor expression in human ovarian granulosa cells. J Clin Endocrinol Metab. 2006;91(6):2239–43. https://doi.org/10.1210/jc.2005-2739.Menon K.M., Menon B. Regulation of luteinizing hormone receptor expression by an RNA binding protein: role of ERK signaling. Indian J Med Res. 2014;140 Suppl(Suppl 1):S112–9.Menon K.M., Menon B. Regulation of luteinizing hormone receptor expression by an RNA binding protein: role of ERK signaling. Indian J Med Res. 2014;140 Suppl(Suppl 1):S112–9.Lunenfeld B., Bilger W., Longobardi S. et al. The development of gonadotropins for clinical use in the treatment of infertility. Front Endocrinol (Lausanne). 2019;10:429. https://doi.org/10.3389/fendo.2019.00429.Lunenfeld B., Bilger W., Longobardi S. et al. The development of gonadotropins for clinical use in the treatment of infertility. Front Endocrinol (Lausanne). 2019;10:429. https://doi.org/10.3389/fendo.2019.00429.Cozzolino M., Mossetti L., Mariani G. et al. The ovarian stimulation regimen does not affect aneuploidy or blastocyst rate. Reprod Biomed Online. 2024;49(2):103851. https://doi.org/10.1016/j.rbmo.2024.103851.Cozzolino M., Mossetti L., Mariani G. et al. The ovarian stimulation regimen does not affect aneuploidy or blastocyst rate. Reprod Biomed Online. 2024;49(2):103851. https://doi.org/10.1016/j.rbmo.2024.103851.Бекетова А.Н., Краснопольская К.В., Назаренко Т.А., Кабанова Д.И. Мочевые и рекомбинантные гонадотропины в программах ЭКО (обзор литературы). Проблемы репродукции. 2014;(3):45–52.Beketova A.N., Krasnopol'skaia K.V., Nazarenko T.A., Kabanova D.I. Urinary and recombinant gonadotropins in IVF (a review). [Mochevye i rekombinantnye gonadotropiny v programmah EKO (obzor literatury)]. Problemy reprodukcii. 2014;(3):45–52. (In Russ.).Ezcurra D., Humaidan P. A review of luteinising hormone and human chorionic gonadotropin when used in assisted reproductive technology. Reprod Biol Endocrinol. 2014;12:95. https://doi.org/10.1186/1477-7827-12-95.Ezcurra D., Humaidan P. A review of luteinising hormone and human chorionic gonadotropin when used in assisted reproductive technology. Reprod Biol Endocrinol. 2014;12:95. https://doi.org/10.1186/1477-7827-12-95.Moro F., Scarinci E., Palla C. et al. Highly purified hMG versus recombinant FSH plus recombinant LH in intrauterine insemination cycles in women ≥35 years: a RCT. Hum Reprod. 2015; 30(1):179–85. https://doi.org/10.1093/humrep/deu302.Moro F., Scarinci E., Palla C. et al. Highly purified hMG versus recombinant FSH plus recombinant LH in intrauterine insemination cycles in women ≥35 years: a RCT. Hum Reprod. 2015; 30(1):179–85. https://doi.org/10.1093/humrep/deu302.Orvieto R. HMG versus recombinant FSH plus recombinant LH in ovarian stimulation for IVF: does the source of LH preparation matter? Reprod Biomed Online. 2019;39(6):1001–6. https://doi.org/10.1016/j.rbmo.2019.08.010.Orvieto R. HMG versus recombinant FSH plus recombinant LH in ovarian stimulation for IVF: does the source of LH preparation matter? Reprod Biomed Online. 2019;39(6):1001–6. https://doi.org/10.1016/j.rbmo.2019.08.010.Pacchiarotti A., Sbracia M., Frega A. et al. Urinary hMG (Meropur) versus recombinant FSH plus recombinant LH (Pergoveris) in IVF: a multicenter, prospective, randomized controlled trial. Fertil Steril. 2010;94(6):2467–9. https://doi.org/10.1016/j.fertnstert.2010.04.035.Pacchiarotti A., Sbracia M., Frega A. et al. Urinary hMG (Meropur) versus recombinant FSH plus recombinant LH (Pergoveris) in IVF: a multicenter, prospective, randomized controlled trial. Fertil Steril. 2010;94(6):2467–9. https://doi.org/10.1016/j.fertnstert.2010.04.035.Tehraninejad E.S, Taghinejad M.F., Rashidi B.H., Haghollahi F. Controlled ovarian stimulation with r-FSH plus r-LH vs. HMG plus r-FSH in patients candidate for IVF/ICSI cycles: an RCT. Int J Reprod Biomed. 2017;15(7):435–40.Tehraninejad E.S, Taghinejad M.F., Rashidi B.H., Haghollahi F. Controlled ovarian stimulation with r-FSH plus r-LH vs. HMG plus r-FSH in patients candidate for IVF/ICSI cycles: an RCT. Int J Reprod Biomed. 2017;15(7):435–40.Nedresky D., Singh G. Physiology, Luteinizing Hormone. 2022 Sep 26. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2025 Jan. 2022 Sep 26.Nedresky D., Singh G. Physiology, Luteinizing Hormone. 2022 Sep 26. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2025 Jan. 2022 Sep 26.Ovarian Stimulation TEGGO, Bosch E., Broer S., Griesinger G. et al. ESHRE guideline: ovarian stimulation for IVF/ICSI†. Hum Reprod Open. 2020;2020(2):hoaa009. https://doi.org/10.1093/hropen/hoaa009.Ovarian Stimulation TEGGO, Bosch E., Broer S., Griesinger G. et al. ESHRE guideline: ovarian stimulation for IVF/ICSI†. Hum Reprod Open. 2020;2020(2):hoaa009. https://doi.org/10.1093/hropen/hoaa009.De Placido G., Mollo A., Alviggi C. et al. Rescue of IVF cycles by HMG in pituitary down-regulated normogonadotrophic young women characterized by a poor initial response to recombinant FSH. Hum Reprod. 2001;16(9):1875–9. https://doi.org/10.1093/humrep/16.9.1875.De Placido G., Mollo A., Alviggi C. et al. Rescue of IVF cycles by HMG in pituitary down-regulated normogonadotrophic young women characterized by a poor initial response to recombinant FSH. Hum Reprod. 2001;16(9):1875–9. https://doi.org/10.1093/humrep/16.9.1875.Ferraretti A.P., Gianaroli L., Magli M.C. et al. Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques. Fertil Steril. 2004;82(6):1521–6. https://doi.org/10.1016/j.fertnstert.2004.06.041.Ferraretti A.P., Gianaroli L., Magli M.C. et al. Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques. Fertil Steril. 2004;82(6):1521–6. https://doi.org/10.1016/j.fertnstert.2004.06.041.Kolibianakis E.M., Collins J., Tarlatzis B.C. et al. Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis. Hum Reprod Update. 2006;12(6):651–71. https://doi.org/10.1093/humupd/dml038.Kolibianakis E.M., Collins J., Tarlatzis B.C. et al. Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis. Hum Reprod Update. 2006;12(6):651–71. https://doi.org/10.1093/humupd/dml038.Humaidan P., Chin W., Rogoff D. et al. Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders. Hum Reprod. 2017;32(3):544–55. https://doi.org/10.1093/humrep/dew360.Humaidan P., Chin W., Rogoff D. et al. Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders. Hum Reprod. 2017;32(3):544–55. https://doi.org/10.1093/humrep/dew360.Mochtar M.H., Danhof N.A., Ayeleke R.O. et al. Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles. Cochrane Database Syst Rev. 2017;5(5):CD005070. https://doi.org/10.1002/14651858.CD005070.pub3.Mochtar M.H., Danhof N.A., Ayeleke R.O. et al. Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles. Cochrane Database Syst Rev. 2017;5(5):CD005070. https://doi.org/10.1002/14651858.CD005070.pub3.Westergaard L.G., Laursen S.B., Andersen C.Y. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum Reprod. 2000;15(5):1003–8. https://doi.org/10.1093/humrep/15.5.1003.Westergaard L.G., Laursen S.B., Andersen C.Y. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum Reprod. 2000;15(5):1003–8. https://doi.org/10.1093/humrep/15.5.1003.Melo P., Eapen A., Chung Y. et al. Controlled ovarian stimulation protocols for assisted reproduction: a network meta-analysis. Cochrane Database Syst Rev. 2025;7(7):CD012586. https://doi.org/10.1002/14651858.CD012586.pub2.Melo P., Eapen A., Chung Y. et al. Controlled ovarian stimulation protocols for assisted reproduction: a network meta-analysis. Cochrane Database Syst Rev. 2025;7(7):CD012586. https://doi.org/10.1002/14651858.CD012586.pub2.Shoham Z., Mannaerts B., Insler V., Coelingh-Bennink H. Induction of follicular growth using recombinant human follicle-stimulating hormone in two volunteer women with hypogonadotropic hypogonadism. Fertil Steril. 1993;59(4):738–42. https://doi.org/10.1016/s0015-0282(16)55852-x.Shoham Z., Mannaerts B., Insler V., Coelingh-Bennink H. Induction of follicular growth using recombinant human follicle-stimulating hormone in two volunteer women with hypogonadotropic hypogonadism. Fertil Steril. 1993;59(4):738–42. https://doi.org/10.1016/s0015-0282(16)55852-x.Platteau P., Nyboe Andersen A., Loft A. et al. Highly purified HMG versus recombinant FSH for ovarian stimulation in IVF cycles: a randomized assessor-blind study. Reprod Biomed Online. 2008;17(2):190–8. https://doi.org/10.1016/s1472-6483(10)60194-0.Platteau P., Nyboe Andersen A., Loft A. et al. Highly purified HMG versus recombinant FSH for ovarian stimulation in IVF cycles: a randomized assessor-blind study. Reprod Biomed Online. 2008;17(2):190–8. https://doi.org/10.1016/s1472-6483(10)60194-0.Pezzuto A., Ferrari B., Coppola F., Nardelli GB. LH supplementation in down-regulated women undergoing assisted reproduction with baseline low serum LH levels. Gynecol Endocrinol. 2010;26(2):118–24. https://doi.org/10.3109/09513590903215516.Pezzuto A., Ferrari B., Coppola F., Nardelli GB. LH supplementation in down-regulated women undergoing assisted reproduction with baseline low serum LH levels. Gynecol Endocrinol. 2010;26(2):118–24. https://doi.org/10.3109/09513590903215516.He W., Lin H., Lv J. et al. The impact of luteinizing hormone supplementation in gonadotropin-releasing hormone antagonist cycles: a retrospective cohort study. Gynecol Endocrinol. 2018;34(6):513–7. https://doi.org/10.1080/09513590.2017.1411473.He W., Lin H., Lv J. et al. The impact of luteinizing hormone supplementation in gonadotropin-releasing hormone antagonist cycles: a retrospective cohort study. Gynecol Endocrinol. 2018;34(6):513–7. https://doi.org/10.1080/09513590.2017.1411473.Paterson N.D., Foong S.C., Greene C.A. Improved pregnancy rates with luteinizing hormone supplementation in patients undergoing ovarian stimulation for IVF. J Assist Reprod Genet. 2012;29(7):579–83. https://doi.org/10.1007/s10815-012-9740-z.Paterson N.D., Foong S.C., Greene C.A. Improved pregnancy rates with luteinizing hormone supplementation in patients undergoing ovarian stimulation for IVF. J Assist Reprod Genet. 2012;29(7):579–83. https://doi.org/10.1007/s10815-012-9740-z.Setti A.S., Braga D., Iaconelli A., Borges E. Improving implantation rate in 2nd ICSI cycle through ovarian stimulation with FSH and LH in GnRH antagonist regimen. Rev Bras Ginecol Obstet. 2021;43(10):749–58. https://doi.org/10.1055/s-0041-1736306.Setti A.S., Braga D., Iaconelli A., Borges E. Improving implantation rate in 2nd ICSI cycle through ovarian stimulation with FSH and LH in GnRH antagonist regimen. Rev Bras Ginecol Obstet. 2021;43(10):749–58. https://doi.org/10.1055/s-0041-1736306.Wang M., Huang R., Liang X. et al. Recombinant LH supplementation improves cumulative live birth rates in the GnRH antagonist protocol: a multicenter retrospective study using a propensity score-matching analysis. Reprod Biol Endocrinol. 2022;20(1):114. https://doi.org/10.1186/s12958-022-00985-4.Wang M., Huang R., Liang X. et al. Recombinant LH supplementation improves cumulative live birth rates in the GnRH antagonist protocol: a multicenter retrospective study using a propensity score-matching analysis. Reprod Biol Endocrinol. 2022;20(1):114. https://doi.org/10.1186/s12958-022-00985-4.Kol S. LH supplementation in ovarian stimulation for IVF: the individual, LH-deficient, patient perspective. Gynecol Obstet Invest. 2020;85(1):1–5. https://doi.org/10.1159/000509162.Kol S. LH supplementation in ovarian stimulation for IVF: the individual, LH-deficient, patient perspective. Gynecol Obstet Invest. 2020;85(1):1–5. https://doi.org/10.1159/000509162.Lehert P., Kolibianakis E.M., Venetis C.A. et al. Recombinant human follicle-stimulating hormone (r-hFSH) plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systematic review and meta-analysis. Reprod Biol Endocrinol. 2014;12:17. https://doi.org/10.1186/1477-7827-12-17.Lehert P., Kolibianakis E.M., Venetis C.A. et al. Recombinant human follicle-stimulating hormone (r-hFSH) plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systematic review and meta-analysis. Reprod Biol Endocrinol. 2014;12:17. https://doi.org/10.1186/1477-7827-12-17.Arvis P., Giraudeau B., Fabbro-Peray P. et al. Effect of recombinant LH supplementation on cumulative live birth rate in poor ovarian responders: a real-world, multicentre controlled study. Reprod Biol Endocrinol. 2021;19:189. https://doi.org/10.1016/j.rbmo.2020.08.035.Arvis P., Giraudeau B., Fabbro-Peray P. et al. Effect of recombinant LH supplementation on cumulative live birth rate in poor ovarian responders: a real-world, multicentre controlled study. Reprod Biol Endocrinol. 2021;19:189. https://doi.org/10.1016/j.rbmo.2020.08.035.Chinta P., Broer S., van Wely M. et al. POSEIDON classification and the proposed treatment options for poor/suboptimal ovarian responders: an update and review. Hum Reprod Open. 2021;2021(1):hoaa070. https://doi.org/10.1093/hropen/hoaa070.Chinta P., Broer S., van Wely M. et al. POSEIDON classification and the proposed treatment options for poor/suboptimal ovarian responders: an update and review. Hum Reprod Open. 2021;2021(1):hoaa070. https://doi.org/10.1093/hropen/hoaa070.Levi-Setti P.E., Zerbetto I., Baggiani A. et al. An observational retrospective cohort trial on 4,828 IVF cycles evaluating different low prognosis patients following the POSEIDON criteria. Front Endocrinol (Lausanne). 2019;10:282. https://doi.org/10.3389/fendo.2019.00282.Levi-Setti P.E., Zerbetto I., Baggiani A. et al. An observational retrospective cohort trial on 4,828 IVF cycles evaluating different low prognosis patients following the POSEIDON criteria. Front Endocrinol (Lausanne). 2019;10:282. https://doi.org/10.3389/fendo.2019.00282.Berker B., Şükür Y.E., Özdemir E.Ü. et al. Human menopausal gonadotropin commenced on early follicular period increases live birth rates in POSEIDON group 3 and 4 poor responders. Reprod Sci. 2021;28(2):488–94. https://doi.org/10.1007/s43032-020-00300-9.Berker B., Şükür Y.E., Özdemir E.Ü. et al. Human menopausal gonadotropin commenced on early follicular period increases live birth rates in POSEIDON group 3 and 4 poor responders. Reprod Sci. 2021;28(2):488–94. https://doi.org/10.1007/s43032-020-00300-9.Marchiani S., Tamburrino L., Benini F. et al. LH supplementation of ovarian stimulation protocols influences follicular fluid steroid composition contributing to the improvement of ovarian response in poor responder women. Sci Rep. 2020;10(1):12907. https://doi.org/10.1038/s41598-020-69325-z.Marchiani S., Tamburrino L., Benini F. et al. LH supplementation of ovarian stimulation protocols influences follicular fluid steroid composition contributing to the improvement of ovarian response in poor responder women. Sci Rep. 2020;10(1):12907. https://doi.org/10.1038/s41598-020-69325-z.Conforti A., Esteves S.C., Di Rella F. et al. The role of recombinant LH in women with hypo-response to controlled ovarian stimulation: a systematic review and meta-analysis. Reprod Biol Endocrinol. 2019;17(1):18. https://doi.org/10.1186/s12958-019-0460-4.Conforti A., Esteves S.C., Di Rella F. et al. The role of recombinant LH in women with hypo-response to controlled ovarian stimulation: a systematic review and meta-analysis. Reprod Biol Endocrinol. 2019;17(1):18. https://doi.org/10.1186/s12958-019-0460-4.Alviggi C., Vigilante L., Cariati F. et al. The role of recombinant LH in ovarian stimulation: what's new? Reprod Biol Endocrinol. 2025;23(Suppl 1):38. https://doi.org/10.1186/s12958-025-01361-8.Alviggi C., Vigilante L., Cariati F. et al. The role of recombinant LH in ovarian stimulation: what's new? Reprod Biol Endocrinol. 2025;23(Suppl 1):38. https://doi.org/10.1186/s12958-025-01361-8.Alviggi C., Pettersson K., Longobardi S. et al. A common polymorphic allele of the LH beta-subunit gene is associated with higher exogenous FSH consumption during controlled ovarian stimulation for assisted reproductive technology. Reprod Biol Endocrinol. 2013;11:51. https://doi.org/10.1186/1477-7827-11-51.Alviggi C., Pettersson K., Longobardi S. et al. A common polymorphic allele of the LH beta-subunit gene is associated with higher exogenous FSH consumption during controlled ovarian stimulation for assisted reproductive technology. Reprod Biol Endocrinol. 2013;11:51. https://doi.org/10.1186/1477-7827-11-51.Ga R., Cheemakurthi R., Kalagara M. et al. Effect of LHCGR gene polymorphism (rs2293275) on LH supplementation protocol outcomes in second IVF cycles: a retrospective study. Front Endocrinol (Lausanne). 2021;12:628169. https://doi.org/10.3389/fendo.2021.628169.Ga R., Cheemakurthi R., Kalagara M. et al. Effect of LHCGR gene polymorphism (rs2293275) on LH supplementation protocol outcomes in second IVF cycles: a retrospective study. Front Endocrinol (Lausanne). 2021;12:628169. https://doi.org/10.3389/fendo.2021.628169.Smitz J., Andersen A.N., Devroey P. et al. Endocrine profile in serum and follicular fluid differs after ovarian stimulation with HP-hMG or recombinant FSH in IVF patients. Hum Reprod. 2007;22(3):676–87. https://doi.org/10.1093/humrep/del445.Smitz J., Andersen A.N., Devroey P. et al. Endocrine profile in serum and follicular fluid differs after ovarian stimulation with HP-hMG or recombinant FSH in IVF patients. Hum Reprod. 2007;22(3):676–87. https://doi.org/10.1093/humrep/del445.Ziebe S., Lundin K., Janssens R. et al. Influence of follicular stimulation with HP-hMG or recombinant FSH on embryo quality parameters and clinical outcome in IVF patients. Reprod Biomed Online. 2007;15(5):539–46. https://doi.org/10.1093/humrep/dem221.Ziebe S., Lundin K., Janssens R. et al. Influence of follicular stimulation with HP-hMG or recombinant FSH on embryo quality parameters and clinical outcome in IVF patients. Reprod Biomed Online. 2007;15(5):539–46. https://doi.org/10.1093/humrep/dem221.Liang Y., Hou X., Chen H. et al. Assisted reproductive technology outcomes in women with normal ovarian response receiving recombinant luteinizing hormone/human menopausal gonadotropin: an observational study. Int J Womens Health. 2024;16:1103–11. https://doi.org/10.2147/IJWH.S454410.Liang Y., Hou X., Chen H. et al. Assisted reproductive technology outcomes in women with normal ovarian response receiving recombinant luteinizing hormone/human menopausal gonadotropin: an observational study. Int J Womens Health. 2024;16:1103–11. https://doi.org/10.2147/IJWH.S454410.Caserta D., Mantovani A., Marci R. et al. Environment and women's reproductive health. Hum Reprod Update. 2011;17(3):418–33. https://doi.org/10.1093/humupd/dmq061.Caserta D., Mantovani A., Marci R. et al. Environment and women's reproductive health. Hum Reprod Update. 2011;17(3):418–33. https://doi.org/10.1093/humupd/dmq061.Witz C.A., Daftary G.S., Doody K.J. et al. Randomized, assessor-blinded trial comparing highly purified human menotropin and recombinant follicle-stimulating hormone in high responders undergoing intracytoplasmic sperm injection. Fertil Steril. 2020;114(2):321–30. https://doi.org/10.1016/j.fertnstert.2020.03.029.Witz C.A., Daftary G.S., Doody K.J. et al. Randomized, assessor-blinded trial comparing highly purified human menotropin and recombinant follicle-stimulating hormone in high responders undergoing intracytoplasmic sperm injection. Fertil Steril. 2020;114(2):321–30. https://doi.org/10.1016/j.fertnstert.2020.03.029.Khair A., Brown T., Markert M. et al. Highly purified human menopausal gonadotropin (HP-hMG) versus recombinant follicle-stimulating hormone (rFSH) for controlled ovarian stimulation in US predicted high-responder patients: a cost-comparison analysis. Pharmacoecon Open. 2023;7(5):851–60. https://doi.org/10.1007/s41669-023-00429-8.Khair A., Brown T., Markert M. et al. Highly purified human menopausal gonadotropin (HP-hMG) versus recombinant follicle-stimulating hormone (rFSH) for controlled ovarian stimulation in US predicted high-responder patients: a cost-comparison analysis. Pharmacoecon Open. 2023;7(5):851–60. https://doi.org/10.1007/s41669-023-00429-8.Conforti A., Esteves S.C., Humaidan P. et al. Recombinant human luteinizing hormone co-treatment in ovarian stimulation for assisted reproductive technology in women of advanced reproductive age: a systematic review and meta-analysis of randomized controlled trials. Reprod Biol Endocrinol. 2021;19(1):91. https://doi.org/10.1186/s12958-021-00759-4.Conforti A., Esteves S.C., Humaidan P. et al. Recombinant human luteinizing hormone co-treatment in ovarian stimulation for assisted reproductive technology in women of advanced reproductive age: a systematic review and meta-analysis of randomized controlled trials. Reprod Biol Endocrinol. 2021;19(1):91. https://doi.org/10.1186/s12958-021-00759-4.Matorras R., Prieto B., Exposito A. et al. Mid-follicular LH supplementation in women aged 35-39 years undergoing ICSI cycles: a randomized controlled study. Reprod Biomed Online. 2009;19(6):879–87. https://doi.org/10.1016/j.rbmo.2009.09.016.Matorras R., Prieto B., Exposito A. et al. Mid-follicular LH supplementation in women aged 35-39 years undergoing ICSI cycles: a randomized controlled study. Reprod Biomed Online. 2009;19(6):879–87. https://doi.org/10.1016/j.rbmo.2009.09.016.Vuong T.N. Phung H.T., Ho M.T. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥ 35 years: a randomized controlled trial. Hum Reprod. 2015;30(5):1188–95. https://doi.org/10.1093/humrep/dev038.Vuong T.N. Phung H.T., Ho M.T. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥ 35 years: a randomized controlled trial. Hum Reprod. 2015;30(5):1188–95. https://doi.org/10.1093/humrep/dev038.Bielfeld A.P., Schwarze J.E., Verpillat P. et al. Effectiveness of recombinant human FSH: recombinant human LH combination treatment versus recombinant human FSH alone for assisted reproductive technology in women aged 35-40 years. Reprod Biomed Online. 2024;48(6):103725. https://doi.org/10.1016/j.rbmo.2023.103725.Bielfeld A.P., Schwarze J.E., Verpillat P. et al. Effectiveness of recombinant human FSH: recombinant human LH combination treatment versus recombinant human FSH alone for assisted reproductive technology in women aged 35-40 years. Reprod Biomed Online. 2024;48(6):103725. https://doi.org/10.1016/j.rbmo.2023.103725.König T..E, van der Houwen L.E., Overbeek A. et al. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study. Hum Reprod. 2013;28(10):2804–12. https://doi.org/10.1093/humrep/det266.König T..E, van der Houwen L.E., Overbeek A. et al. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study. Hum Reprod. 2013;28(10):2804–12. https://doi.org/10.1093/humrep/det266.Bosch E. Comment on 'Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years old or older undergoing IVF/ICSI: a randomized controlled multicentre study'. Hum Reprod. 2014;29(3):636–7. https://doi.org/10.1093/humrep/det431.Bosch E. Comment on 'Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years old or older undergoing IVF/ICSI: a randomized controlled multicentre study'. Hum Reprod. 2014;29(3):636–7. https://doi.org/10.1093/humrep/det431.

The authors declare that there are no conflicts of interest present.